Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Pembrolizumab Plus Cetuximab in Betel Nut-Associated Oral Cavity Squamous Cell Carcinoma
NCT07733466Phase 2Not yet recruiting
- Sponsor
- Peter Brett Associates
- Start
- Aug 2026
- Primary completion
- Jul 2030
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, KL-140 in oral cavity squamous cell carcinoma (OCSCC), sponsored by Peter Brett Associates. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
pembrolizumabKL-140
03
Conditions
oral cavity squamous cell carcinoma (OCSCC)
Beyond the preview
Go deeper on NCT07733466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07733466.